The effectiveness of Novartis' (NVS) immune-system drug Certican was confirmed in the largest...
Monday, November 12, 2012, 9:06 AM ETThe effectiveness of Novartis' (NVS) immune-system drug Certican was confirmed in the largest trial to date of liver-transplant patients, with the treatment also able to improve renal function in the two-year Phase III study. Certican is approved in the EU for liver transplant patients, with an FDA approval decision expected at the end of the year. (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles